KRW 11520.0
(-0.78%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 168 Million KRW | -99.44% |
2022 | 30.04 Billion KRW | 1730.01% |
2021 | 1.64 Billion KRW | 4.4% |
2020 | 1.57 Billion KRW | -71.23% |
2019 | 5.46 Billion KRW | -47.58% |
2018 | 10.42 Billion KRW | -32.4% |
2017 | 15.42 Billion KRW | 9.93% |
2016 | 14.03 Billion KRW | 66.81% |
2015 | 8.41 Billion KRW | 221.15% |
2014 | 2.62 Billion KRW | 0.0% |
2013 | - KRW | -100.0% |
2012 | 10.59 Billion KRW | -26.55% |
2011 | 14.43 Billion KRW | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q2 | 30.14 Billion KRW | 35787.67% |
2024 Q1 | 84 Million KRW | -50.0% |
2023 Q4 | 168 Million KRW | -54.19% |
2023 Q3 | 366.75 Million KRW | -15.94% |
2023 Q1 | 30.86 Billion KRW | 2.72% |
2023 FY | 168 Million KRW | -99.44% |
2023 Q2 | 436.29 Million KRW | -98.59% |
2022 Q1 | 16.52 Billion KRW | 906.42% |
2022 FY | 30.04 Billion KRW | 1730.01% |
2022 Q2 | 45.79 Billion KRW | 177.11% |
2022 Q3 | 49.01 Billion KRW | 7.04% |
2022 Q4 | 30.04 Billion KRW | -38.7% |
2021 FY | 1.64 Billion KRW | 4.4% |
2021 Q1 | 1.47 Billion KRW | -6.2% |
2021 Q2 | 1.09 Billion KRW | -25.71% |
2021 Q3 | 1.65 Billion KRW | 51.22% |
2021 Q4 | 1.64 Billion KRW | -0.92% |
2020 FY | 1.57 Billion KRW | -71.23% |
2020 Q1 | 4.19 Billion KRW | -23.24% |
2020 Q2 | 42.99 Billion KRW | 924.58% |
2020 Q3 | 1.65 Billion KRW | -96.16% |
2020 Q4 | 1.57 Billion KRW | -4.86% |
2019 Q3 | 6.74 Billion KRW | -16.0% |
2019 Q1 | 9.46 Billion KRW | -9.3% |
2019 FY | 5.46 Billion KRW | -47.58% |
2019 Q4 | 5.46 Billion KRW | -18.93% |
2019 Q2 | 8.02 Billion KRW | -15.14% |
2018 Q3 | 11.67 Billion KRW | -9.67% |
2018 FY | 10.42 Billion KRW | -32.4% |
2018 Q4 | 10.42 Billion KRW | -10.7% |
2018 Q2 | 12.92 Billion KRW | -8.82% |
2018 Q1 | 14.17 Billion KRW | -8.1% |
2017 Q1 | 14.03 Billion KRW | 0.0% |
2017 Q2 | 11.4 Billion KRW | -18.75% |
2017 Q3 | 12.2 Billion KRW | 7.04% |
2017 Q4 | 15.42 Billion KRW | 26.41% |
2017 FY | 15.42 Billion KRW | 9.93% |
2016 FY | 14.03 Billion KRW | 66.81% |
2016 Q4 | 14.03 Billion KRW | -0.0% |
2016 Q3 | 14.03 Billion KRW | 0.0% |
2016 Q2 | 14.03 Billion KRW | 0.0% |
2015 Q4 | 8.41 Billion KRW | 0.0% |
2015 FY | 8.41 Billion KRW | 221.15% |
2014 FY | 2.62 Billion KRW | 0.0% |
2013 FY | - KRW | -100.0% |
2012 FY | 10.59 Billion KRW | -26.55% |
2011 FY | 14.43 Billion KRW | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Yuyu Pharma, Inc. | 13.64 Billion KRW | 98.768% |
Dong-A Socio Holdings Co., Ltd. | 202.06 Billion KRW | 99.917% |
Ildong Holdings Co., Ltd. | 29.87 Billion KRW | 99.438% |
HANDOK Inc. | 123.78 Billion KRW | 99.864% |
Kukje Pharma Co., Ltd. | 475.74 Million KRW | 64.687% |
Yuhan Corporation | 60.23 Billion KRW | 99.721% |
Dong-A ST Co., Ltd. | 161.99 Billion KRW | 99.896% |
SAMSUNG PHARM. Co., LTD. | 101.81 Million KRW | -65.001% |
Hanmi Pharm. Co., Ltd. | 82.02 Billion KRW | 99.795% |
Hanall Biopharma Co.,Ltd | 590.3 Million KRW | 71.54% |
Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | 97.223% |
Dong Sung Bio Pharm.Co.,Ltd. | 18.52 Billion KRW | 99.093% |
MYUNGMOON Pharm co.,Ltd | 12.58 Billion KRW | 98.665% |
Hana Pharm Co., Ltd. | 1.59 Billion KRW | 89.492% |
Yuyu Pharma, Inc. | 13.64 Billion KRW | 98.768% |
Ilsung Pharmaceuticals Co., Ltd. | 119.67 Million KRW | -40.376% |
REYON Pharmaceutical Co., Ltd. | 121 Billion KRW | 99.861% |
Aprogen pharmaceuticals,Inc. | 32 Billion KRW | 99.475% |
JW Holdings Corporation | 20.65 Billion KRW | 99.187% |
Ildong Pharmaceutical Co., Ltd. | 14.82 Billion KRW | 98.867% |
Chong Kun Dang Pharmaceutical Corp. | 30 Billion KRW | 99.44% |
JW Pharmaceutical Corporation | 30 Billion KRW | 99.44% |
Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | 23.274% |
Hyundai Pharmaceutical Co., Ltd. | 580.64 Million KRW | 71.067% |
Samil Pharmaceutical Co.,Ltd | 49.56 Billion KRW | 99.661% |
Jeil Pharmaceutical Co.,Ltd | 4.45 Billion KRW | 96.226% |
Yuyu Pharma, Inc. | 13.64 Billion KRW | 98.768% |
Kwang Dong Pharmaceutical Co., Ltd. | 19.02 Billion KRW | 99.117% |
Daewoong pharmaceutical Co.,Ltd | 93.41 Billion KRW | 99.82% |
JW Pharmaceutical Corporation | 30 Billion KRW | 99.44% |
Yuhan Corporation | 60.23 Billion KRW | 99.721% |
Jeil Pharma Holdings Inc | 10.5 Billion KRW | 98.4% |
Yungjin Pharm. Co., Ltd. | 40.37 Billion KRW | 99.584% |
Suheung Co., Ltd. | 74 Billion KRW | 99.773% |
JW Pharmaceutical Corporation | 30 Billion KRW | 99.44% |
Samjin Pharmaceuticals Co., Ltd. | 4.16 Billion KRW | 95.968% |
Korea United Pharm Inc. | 10.96 Billion KRW | 98.468% |
CKD Bio Corp. | 69.43 Billion KRW | 99.758% |
Daewon Pharmaceutical Co., Ltd. | 34.57 Billion KRW | 99.514% |
Dongwha Pharm.Co.,Ltd | 16.12 Billion KRW | 98.958% |
Whan In Pharm Co.,Ltd. | 307.05 Million KRW | 45.287% |
Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | 23.274% |
Chong Kun Dang Holdings Corp. | 72.11 Billion KRW | 99.767% |
Boryung Corporation | 151.7 Billion KRW | 99.889% |
Bukwang Pharmaceutical Co., Ltd. | 78.52 Billion KRW | 99.786% |
Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | 97.223% |